Insider Selling: Kestra Medical Technologies (NASDAQ:KMTS) CFO Sells $90,545.00 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) CFO Vaseem Mahboob sold 3,980 shares of the stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $22.75, for a total transaction of $90,545.00. Following the completion of the transaction, the chief financial officer owned 108,099 shares of the company’s stock, valued at $2,459,252.25. This represents a 3.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Vaseem Mahboob also recently made the following trade(s):

• On Monday, August 3rd, Vaseem Mahboob sold 5,391 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $23.80, for a total transaction of $128,305.80.
• On Friday, July 31st, Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.61, for a total value of $199,352.37.

Kestra Medical Technologies Stock Down 3.4%

Shares of NASDAQ KMTS opened at $25.06 on Thursday. The firm has a market cap of $1.47 billion, a P/E ratio of -10.36 and a beta of 0.58. Kestra Medical Technologies, Ltd. has a 1 year low of $14.10 and a 1 year high of $30.00. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41. The firm’s 50 day moving average price is $22.78 and its 200 day moving average price is $22.52.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). The firm had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. As a group, sell-side analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. BTIG Research boosted their price objective on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. The Goldman Sachs Group cut their target price on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Wolfe Research set a $30.00 price target on Kestra Medical Technologies in a research note on Wednesday, July 15th. Oppenheimer initiated coverage on Kestra Medical Technologies in a report on Tuesday, July 21st. They set a “market perform” rating on the stock. Finally, Weiss Ratings cut shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 16th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $27.83.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD grew its stake in shares of Kestra Medical Technologies by 137.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock worth $115,878,000 after acquiring an additional 2,529,851 shares during the last quarter. Brown Advisory Inc. raised its stake in Kestra Medical Technologies by 34.1% during the 4th quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock valued at $44,775,000 after purchasing an additional 428,996 shares during the last quarter. Alliancebernstein L.P. raised its stake in Kestra Medical Technologies by 13.7% during the 3rd quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock valued at $35,449,000 after purchasing an additional 179,885 shares during the last quarter. Eventide Asset Management LLC boosted its holdings in Kestra Medical Technologies by 5.4% in the 4th quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock valued at $33,671,000 after purchasing an additional 65,288 shares during the period. Finally, Franklin Resources Inc. grew its position in Kestra Medical Technologies by 180.8% in the 4th quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock worth $25,221,000 after purchasing an additional 612,343 shares during the last quarter.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.